The ASCU/LSIL Triage Study for Cervical Cancer: ALTS study

ALTS是一项研究，旨在找到最好的方法来帮助妇女和她们的医生决定如何处理轻微异常和非常常见的巴氏试验结果，即ASCUS和LSIL。在美国，每年约有300万女性被诊断出患有ASCUS和Lsil。由国家癌症研究所组织和资助的ALTS包括5000多名女性。它于1996年11月开始，2000年底结束。对试验结果的数据分析正在进行中。 ASCUS代表意义不明的不典型鳞状细胞，LsIL代表低度鳞状上皮内病变。这些轻微的异常大多数不需要治疗就会消失，但有些可能是癌前状态的信号，或者很少是癌症的信号。ALTS研究了三种管理这些异常情况的方法： 立即阴道镜检查(宫颈放大观察和检查) 重复巴氏试验 人类乳头瘤病毒(HPV)检测，这是一种与宫颈癌有关的感染

ALTS was a study undertaken to find the best way to help women and their doctors decide what to do about the mildly abnormal and very common Pap test results known as ASCUS and LSIL. About three million women in the United States are diagnosed with ASCUS and LSIL each year. Organized and funded by the National Cancer Institute, ALTS included more than 5,000 women. It began in November 1996 and concluded at the end of 2000. Data analysis of the trial's findings is ongoing. ASCUS stands for atypical squamous cells of undetermined significance and LSIL for low-grade squamous intraepithelial lesions. Most of these mild abnormalities will go away without treatment, but some may signal a precancerous condition or, rarely, cancer. ALTS looked at three ways to manage these abnormalities: immediate colposcopy (magnified viewing and testing of the cervix) repeat Pap tests testing for human papillomavirus (HPV), an infection linked to cervical cancer